Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Trial Profile

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone; Methylprednisolone; Methylprednisolone
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genmab; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 20 Feb 2020 PK analysis results of splitting the first daratumumab IV dose into two separate infusions published in the Advances in Therapy
    • 04 Dec 2018 Results reporting on ten patients that are still responding to DARA therapy, several years after their inclusion in the GEN501 and GEN503 trials presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 17 Jun 2018 Results assessing the effect of Daratumumab on normal plasma cells, polyclonal immunoglobulins and vaccination responses in extensively pretreated myeloma patients using healthy controls baseline CD38 expression levels data, presented at the 23rd Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top